Form 4: Precipio Director Richard A. Sandberg Reports Stock Option Repricing

Director Richard A. Sandberg reports adjustments to stock options in Precipio, Inc. following a board-approved repricing.

Summary

• Richard A. Sandberg, a director at Precipio, Inc., filed a Form 4 on September 6, 2024, reporting changes in beneficial ownership due to a stock option repricing.
• The repricing, approved by the Board of Directors on August 30, 2024, became effective on August 31, 2024.
• The exercise price of several stock option grants was adjusted to $6.56 per share, reflecting the fair market value of Precipio's common stock on the effective date.
• Sandberg acquired and disposed of options at various strike prices, including $43.60, $42.80, $26.00, $42.00, $64.40, and $30.80, with the new exercise price being $6.56.
• The repriced options will revert to their original exercise price if Sandberg's service with the Issuer is terminated with cause or by Sandberg, or if the option is exercised, prior to the first anniversary of the effective date.

Sentiment

Score: 5

Explanation: The document itself is neutral, reporting a procedural change. The sentiment depends on the investor's view of the company's prospects and the impact of the repricing on shareholder value.

Positives

• The repricing of stock options could incentivize the director to remain with the company and improve performance.
• The new exercise price reflects the fair market value of the company's common stock on the effective date.

Negatives

• The repricing may dilute existing shareholders' equity if the options are exercised.
• The repricing could be perceived negatively if the original option prices were significantly higher, suggesting a decline in the stock's perceived value at the time of the original grants.

Risks

• The repriced options reverting to their original exercise price if Sandberg's service is terminated with cause or by Sandberg within one year could create uncertainty.
• The potential dilution of existing shareholders' equity if the options are exercised remains a risk.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the option repricing.

Management Comments

• The Issuer's Board of Directors approved an option repricing (the 'Repricing'), effective as of August 31, 2024 (the 'Effective Date').
• All of the other terms of the options remain unchanged.

Industry Context

Option repricing is a common practice in the biotech industry to retain and incentivize key personnel, especially when a company's stock price has underperformed.

Comparison to Industry Standards

• Repricing of options is a fairly common practice, especially in volatile sectors like biotech, where stock prices can fluctuate significantly.
• Companies like Novavax and Sorrento Therapeutics have also undertaken similar repricing actions in the past to maintain employee motivation and retention.
• The specific terms, such as the reversion clause if employment is terminated, are fairly standard in executive compensation packages.

Stakeholder Impact

• Shareholders may experience dilution if the options are exercised.
• Employees with options benefit from the lower exercise price.
• The repricing aims to retain and incentivize key personnel, potentially benefiting the company's long-term performance.

Key Dates

Keywords

stock options, repricing, Precipio, director, Richard A. Sandberg, Form 4, beneficial ownership, equity securities